CoChat

Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study

Open access

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate the effects of metformin use on the survival of inoperable non-small cell lung cancer (NSCLC) patients with diabetes using the Taiwanese National Health Insurance Research Database. RESEARCH DESIGN AND METHODS: In total, 7,620 patients were eligible in this study, among them, 3,578 patients were metformin users and 4,042 were non-users. Propensity score matching was used to reduce possible confounding factors. In total, 4,182 patients (2,091 matched pairs) were included in the matched cohort. Cox proportional hazard model with time-dependent covariate were also applied to evaluate the association between metformin use and overall survival (OS). RESULTS: A total of 3,578 patients were metformin users at the time of diagnosis of NSCLC. Cox proportional hazard model with time-dependent covariate revealed that metformin use was associated with a significantly longer OS (HR: 0.85, 95.0% CI: 0.80-0.90). The survival benefit of metformin use was maintained after propensity score matching at a ratio of 1:1 (HR: 0.90, 95.0% CI: 0.84-0.97). CONCLUSIONS: Metformin use is associated with longer OS in inoperable NSCLC patients with diabetes, suggesting a potential anti-tumorigenic effect for metformin. Further research is needed to investigate the actual role of metformin in the treatment of NSCLC patients with diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0191129

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Flow chart of patient selection from the Registry for Catastrophic Illness Patient Database (RCIPD). ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; NSCLC, non-small cell lung cancer.
Fig 1 Flow chart of patient selection from the Registry for Catastrophic Illness Patient Database (RCIPD). ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; NSCLC, non-small cell lung cancer.CC BY · PubMed Central
Fig 2 Subgroup analysis of adjusted hazard ratios (HRs) of risk factors for metformin-related mortality in the matched cohorts.
Fig 2 Subgroup analysis of adjusted hazard ratios (HRs) of risk factors for metformin-related mortality in the matched cohorts.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 1

  1. S Brulé, 2015, Non-small cell lung cancer: Two decades of progress, Oncology Exchange, 14, 12

Cited by

See all 29

Metadata

Authors
Chuang, M.-C., Yang, Y.-H., Tsai, Y.-H., Hsieh, M.-J., Lin, Y.-C., Lin, C.-K., Chen, P.-C., & Yang, T.-M.
Affiliations
  • Chang Gung University (TW)
  • Chang Gung Memorial Hospital (TW)
  • Chiayi Chang Gung Memorial Hospital (TW)
  • National Taiwan University (TW)
Corresponding author
Yang, Tsung-Ming
Venue
PLOS ONE
Published
2018-01-12
Volume
13
Issue
1
Pages
e0191129
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2783659013
Cited by
29
References
38
Citations by year
2024: 1 · 2023: 3 · 2022: 4 · 2021: 11 · 2020: 5 · 2019: 2 · 2018: 3
FWCI
1.87
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Chiayi Chang Gung Memorial Hospital, Taiwan (CLRPG6G0041)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
metformin, non-small cell lung cancer, diabetes mellitus, inoperable lung cancer, overall survival, anti-tumorigenic effects, drug repurposing
MeSH terms
Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Diabetes Mellitus, Female, Humans, Hypoglycemic Agents, Lung Neoplasms, Male, Metformin, Middle Aged, Retrospective Studies, Taiwan, Proportional Hazards Models, Survival Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study. https://app.cochat.ai/papers/10.1371/journal.pone.0191129
The paper
Chuang, M.-C., Yang, Y.-H., Tsai, Y.-H., Hsieh, M.-J., Lin, Y.-C., Lin, C.-K., Chen, P.-C., & Yang, T.-M. (2018). Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0191129

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.